Deuterium-Enriched Lenalidomide Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lenalidomide pharmaceuticals have limited effectiveness due to natural abundance of deuterium, which restricts the therapeutic potential of the compound, necessitating the development of deuterium-enriched forms for enhanced therapeutic benefits, particularly in treating multiple myeloma.
Innovation Solution
Deuterium-enriched lenalidomide or its pharmaceutically acceptable salts are synthesized by exchanging hydrogen atoms with deuterium, achieving enrichment levels above natural abundance, thereby creating novel compounds with increased therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deuterium-enriched lenalidomide is synthesized, then therapeutic efficacy is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the isotopic composition of hydrogen atoms in lenalidomide, specifically enriching deuterium content at designated positions. This changes the physical-chemical parameters of the molecule (mass, bond strength, metabolic stability) to enhance therapeutic efficacy while maintaining the core chemical structure and pharmacological activity of lenalidomide.
Solution Approach 2:
The patent implements local quality by selectively deuterating specific positions in the lenalidomide molecule rather than uniformly enriching all hydrogen atoms. The deuterium enrichment is targeted at particular carbon positions (e.g., C2, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C89, C90, C91, C92, C93, C94, C95, C96, C97, C98, C99, C100) to optimize metabolic stability and therapeutic effect while minimizing manufacturing complexity through targeted synthesis strategies.
2Reliability
If deuterium enrichment is increased, then therapeutic potential is enhanced, but production cost increases
Solution Approach 1:
The patent applies partial action by achieving deuterium enrichment at sufficient levels to provide therapeutic benefit without requiring complete (100%) deuterium substitution at all positions. The deuterium enrichment percentage at each position is optimized to provide adequate metabolic stability and therapeutic effect while avoiding the exponentially increasing costs associated with achieving complete deuteration. This allows production at economically viable levels.
3Stability of the object's composition
If deuterium substitution is performed, then metabolic stability is improved, but synthesis difficulty increases
Solution Approach 1:
The patent applies preliminary action by incorporating deuterium atoms at strategic positions during the early stages of synthesis rather than attempting post-synthesis deuteration. This allows the deuterium-enriched intermediates to be carried through subsequent synthetic steps, reducing the number of separate deuteration operations required and simplifying the overall synthesis pathway while maintaining metabolic stability benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterium-enriched lenalidomide compositions provide a therapeutically effective treatment for multiple myeloma by increasing the deuterium content beyond natural levels, enhancing the compound's therapeutic potential and treatment efficacy.
Implementation Method 1
deuterium-enriched lenalidomide or its pharmaceutically acceptable salts are synthesized by exchanging hydrogen atoms with deuterium, achieving enrichment levels above natural abundance
Data Source
AI summary
The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.